Original paper
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Abstract
Recurrent or metastatic cervical cancer (r/mCC) is a global medical problem with few effective treatments, especially in the second- or third-line settings where available therapies have very limited activity. The phase 2 study innovaTV 204 was conducted to assess the potential of tisotumab vedotin, a tissue factor–directed antibody–drug conjugate, to address this high unmet need in patients with r/mCC. Patients with r/mCC with disease...
Paper Details
Title
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Published Date
Sep 1, 2020
Journal
Volume
31
Pages
S1162 - S1163
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History